Efficacy of newer medications for treating depression in primary care patients

Mulrow, Cynthia D.; Williams, John W; Chiquette, Elaine; Aguilar, Christine; Noël, Polly Hitchcock; Lee, Shuko; Cornell, John E.; Stamm, Karen

doi:10.1016/s0002-9343(99)00316-2

Cited by 112 publications

(83 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, even among patients who receive treatment, response and remission rates with current treatments are low, with over 50% failing to achieve remission in clinical trials of new antidepressants. [10][11][12][13][14][15] In six recent prospective observational community studies, [16][17][18][19][20][21] nonresponse rates ranged from 10 to 51%, partial response rates ranged from 11 to 45%, and remission rates ranged from 25 to 65%.…”

Section: Introductionmentioning

confidence: 99%

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

et al. 2009

View full text Add to dashboard Cite

Objective: To characterize the spectrum of clinical outcomes achieved with depression treatment and the associated impact on quality of life (QOL), functional status, overall well-being, health-care costs, and productivity. Sources: Electronic databases including Medline were searched for English language sources between 1995 and 2007 using key words of depression, nonresponse, partial response, and remission and QOL, functional status, utility, cost, and productivity. Study selection: Relevant abstracts were obtained for 488 references and full-text articles were reviewed that included primary data and compared outcomes by treatment response. Data were abstracted from 26 full-text articles. Data abstraction: Detailed evidence tables were prepared with the relevant data as well as information on the study design. All data abstracted were checked for accuracy. Synthesis: Treatment remitters and partial responders reported clinically and statistically significant improvements in QOL, functional status, and overall well-being compared to nonresponders. Annual health-care costs and productivity losses were significantly lower for remitters and partial responders compared to nonresponders. Conclusions: The reduced disease burden for remitters and partial responders compared to nonresponders indicates that new treatment strategies that improve the rates of response/remission with initial treatment might have value to patients and to society. Depression and Anxiety 26:83-97, 2009.

show abstract

Section: Introductionmentioning

confidence: 99%

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

et al. 2009

View full text Add to dashboard Cite

show abstract

“…First, a substantial proportion of undetected depressed patients have persistently poor outcomes over the course of one year (Goldberg et al 1998;Rost et al 1998). Secondly, there is evidence for the efficacy of both pharmacological and psychotherapeutic interventions for the treatment of MDD in primary care (Mulrow et al 2000;Schulberg et al 2002). The third and most important piece of evidence is provided by recent systematic reviews of primary-care trials, which have concluded that, compared with usual care, quality improvement efforts aimed at improving detection of depression can improve patients' outcomes provided that those recognized receive adequate treatment and follow-up (Pignone et al 2002;Bijl et al 2004).…”

Section: Introductionmentioning

confidence: 99%

Accuracy of diagnosing depression in primary care: the impact of chronic somatic and psychiatric co-morbidity

et al. 2005

View full text Add to dashboard Cite

Background. Depression is highly co-morbid with both psychiatric and chronic somatic disease. These types of co-morbidity have been shown to exert opposite effects on underdiagnosis of depression by general practitioners (GPs). However, past research has not addressed their combined effect on underdiagnosis of depression.Method. Co-morbidity data on 191 depressed primary-care patients selected by a two-stage sampling procedure were analysed. Diagnoses of major depression and/or dysthymia in the last 12 months were assessed using a standardized psychiatric interview (CIDI) and compared with depression diagnoses registered by GPs in patient contacts during the same period. Presence of psychiatric and chronic somatic co-morbidity was determined using the CIDI and contact registration, respectively.Results. Regression analysis showed a significant interaction effect between psychiatric and chronic somatic co-morbidity on GPs’ diagnosis of depression, while taking into account the effects of sociodemographic variables, depression severity and number of GP contacts. Subsequent stratified analysis revealed that in patients without chronic somatic co-morbidity, a lower educational level, a less severe depression, and fewer GP contacts all significantly increased the likelihood of not being diagnosed as depressed. In contrast, in patients with chronic somatic co-morbidity, only having no psychiatric co-morbidity significantly decreased the likelihood of receiving a depression diagnosis.Conclusions. Our results indicate that the effects of psychiatric co-morbidity and other factors on underdiagnosis of depression by GPs differ between depressed patients with and without chronic somatic co-morbidity. Efforts to improve depression diagnosis by GPs seem to require different strategies for depressed patients with and without chronic somatic co-morbidity.

show abstract

“…2 Of the estimated 13% that will experience MDD in their lifetimes, 20% will experience chronic depression and 60-85% will experience relapse or recurrence. 2,3 Providers have access to several effective and efficacious treatment options, including a wide array of antidepressant medications [4][5][6][7][8] and psychotherapeutic interventions. [9][10][11][12][13] For chronic MDD, a combination of psychotherapy and medication has been found to be the most effective.…”

mentioning

confidence: 99%

Examination of the Utility of Psychotherapy for Patients with Treatment Resistant Depression: A Systematic Review

2010

View full text Add to dashboard Cite

Efficacy of newer medications for treating depression in primary care patients

Cited by 112 publications

References 40 publications

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

Accuracy of diagnosing depression in primary care: the impact of chronic somatic and psychiatric co-morbidity

Examination of the Utility of Psychotherapy for Patients with Treatment Resistant Depression: A Systematic Review

Contact Info

Product

Resources

About